The use of low-molecular-weight heparin (LMWH) anticoagulation for patients with acute coronary syndromes (ACS) in whom an invasive procedure is planned is difficult in the absence of an established, safe, and effective method of conversion from a standard LMWH anticoagulation regimen to the high intensity target that is the standard for percutaneous coronary intervention (PCI). Registries and single center stud-ies have described the outcome of PCI performed with intravenous or subcutaneous dalteparin and enoxaparin without monitoring, often guided by assumptions from pharmacokinetic models (1-7), but models may not be applicable to all patients or clinical situations and some method of monitored dose titration is being sought.
Summary:
The objective of this study was to examine the pharmacokinetics of intravenous dalteparin (Fragmin, Pharmacia-Upjohn, Peapack, NJ) and to assess the accuracy of standard coagulationbased monitoring techniques as an estimate of drug concentration with which to guide dosing. Knowledge of the kinetic behavior of low-molecular-weight heparins (LMWHs) and the possible utility of coagulation times for monitoring may aid in the development of safe and effective dosing algorithms for percutaneous coronary interventions. Twenty normal volunteers were treated at 2-week intervals with each of three intravenous dalteparin doses. Measurement of anti-IIa, anti-Xa, activated partial thromboplastin time (aPTT), activated clotting time (ACT), and low-range ACT was performed at baseline and at seven additional time points over 8 hours. The halflife of intravenous dalteparin is 77 minutes with slight dose-related variation. The aPTT, LR-ACT, and standard ACT are prolonged after dalteparin administration with the increase closely correlated to anti-Xa activity (aPTT, r = 0.85; LR-ACT, r = 0.79). Classification of anticoagulation intensity range using aPTT or LR-ACT in comparison to anti-Xa activity (0.5-0.99, 1.0-1.49, 1.5-2, >2) displays a level of agreement (kappa: aPTT = 0.69, LR-ACT = 0.59) that is comparable to values reported for coagulation time guidance of unfractionated heparin administration. Standard coagulation times are sensitive to the anticoagulant effect of dalteparin with a degree of correlation that suggests their utility for estimating drug concentration during high dose therapy. Trials establishing a relationship between monitoring and clinical efficacy, and the risk/reward of different treatment ranges alone or in combination with GPIIb/IIIa inhibitors and clopidogrel, are necessary. Key Words: Low-molecular-weight heparin-Activated clotting time-Activated partial thromboplastin time-Pharmacokinetics. performed a pharmacokinetic and monitoring study in healthy volunteers to determine the halflife of potentially therapeutic doses of dalteparin and to assess the accuracy of standard coagulation-based monitoring methods against a standard of anti-factor Xa activity.
MATERIALS AND METHODS
The study protocol was approved by the St. Luke's Episcopal Hospital Institutional Review Board. Twenty volunteers (10 males and 10 females) with no history of chronic illness, bleeding diathesis, recent trauma, or surgical procedure were recruited and asked to sign informed consent. All participants completed a screening questionnaire and laboratory assessment to ensure normal coagulation status, blood counts, and renal function. Female participants were screened for pregnancy.
Reagents
Activated partial thromboplastin time (aPTT; Actin FS), chromogenic anti-Xa (Berichrom Heparin), and anti-thrombin III (Berichrom AT III) assays were performed on a BCS coagulation analyzer (Dade-Behring, Marburg, Germany). Reagents were manufactured by Dade-Behring. Heparin anti-IIa levels were determined with Spectrolyse Heparin Anti-IIa kits (Biopool International, Ventura, CA) using an STA instrument (Diagnostica Stago, Parsippany, NJ). Cartridges for standard and low-range activated clotting times (ACT, LR-ACT) were used on a Medtronic ACT II instrument (cartridges and instrument manufactured by Medtronic, Inc, Minneapolis, MN).
Treatment
On 3 separate days, each 2 weeks apart, study participants underwent placement of an intravenous catheter into the antecubital vein and withdrawal of baseline laboratory samples. Dalteparin was administered intravenously at 40, 60, or 80 IU/kg followed by 10 mL of saline flush. At the time of dosing, body weight and the exact time of drug administration were recorded. Using the peripheral IV catheter, standard ACT (HemoTec), LR-ACT, (HemoTec), aPTT, anti-IIa, and anti-Xa activities were measured at baseline and at 5, 15, 30, 45, 60, 240, and 480 minutes after intravenous administration of dalteparin. A discard volume of 10 mL was with-drawn from the catheter just before withdrawal of specimens. ACT and LR-ACT samples were tested immediately upon blood withdrawal. Separate specimens were collected in citrated tubes for measurement of aPTT, anti-Xa, and anti-IIa activity. Plasma was separated as soon as possible by centrifuge at 2000G for 20 minutes. Samples for anti-Xa and anti-IIa activity and prothrombin were frozen at 0°C for transport.
Analysis
Participant demographics are described using mean and standard deviation. For the purposes of pharmacokinetic calculations, the following parameters were derived: body mass index (kg/M 2 ), ideal body weight, body surface area (0.20247 × ht (M) 0.725 × wt (kg) 0.425 ), and creatinine clearance (Cockroft-Gault).
Pharmacokinetic calculations were performed using measured anti-Xa concentrations at various time points assuming bioavailability of 100%. Pooled anti-Xa and anti-IIa values were used to calculate population pharmacokinetics. Drug clearance and T 1 ⁄ 2 were calculated with noncompartmental methods using log-trapezoidal integration as well as nonlinear least squares regression models fitted to a mono-or bi-exponential decay. Statistical analysis and regression were performed using an EXCEL spreadsheet and Analyse-it (Analyse-it Software, Ltd., Leeds, England) 1.65 data analysis package. Comparisons of group values were performed using ANOVA . Relationships between derived individual pharmacokinetic parameters of volume distribution and clearance and baseline demographic data and derived parameters were examined using linear regression. Pearson's correlation coefficient was used to measure the association between anti-IIa, anti-Xa, aPTT, LR-ACT, and ACT.
Using anti-Xa activity as the gold standard measure of dalteparin concentration, the ability of coagulation times to identify threshold drug concentrations was assessed creating receiver operator characteristic (ROC) curves. Threshold anti-Xa activities used were, 0.5, 1.0, 1.5, and 2.0 U/mL. From the ROC curves, the most efficient coagulation times identifying samples as above or below threshold values were identified and used to categorize samples into broad ranges of anticoagulation intensity. The agreement between anti-Xa and coagulation time classification was assessed using the weighted Kappa (κ w ) statistic.
RESULTS
Participant demographics and derived parameters are displayed in Table 1 . There were no adverse events observed as a result of dalteparin administration. One volunteer could not participate in the 80 IU/kg dosing session due to interval illness unrelated to drug administration. Therefore, there were 472 samples collected for each test method. Results were unavailable for 16 anti-IIa, 12 anti-Xa, 1 aPTT, 10 LR-ACT, and 2 ACT specimens. Reasons for unavailability included specimen mishandling in transport and device failure. A single outlier in the 80 IU/kg dalteparin dose displayed an anticoagulant response, peak anti-Xa activity, and drug T 1 ⁄ 2 that suggested subcutaneous drug administration perhaps due to venous catheter failure. This individual displayed anticoagulant response, peak anti-Xa, and drug clearance after the 40 IU/kg and 60 IU/kg that was similar to those of his peers. Therefore, the outlier values were excluded in determinations of drug pharmacokinetics but not for analysis of coagulation time accuracy.
Pharmacokinetics
Pharmacokinetic parameters are displayed in Table 2 . The volume of distribution of dalteparin anti-Xa activity was not associated with dose or any baseline parameter other than body weight. The half-life of anti-Xa activity rose (ANOVA, p=0.002) with each increment in dose. The association between dose and T 1 ⁄ 2 was clarified by comparing to peak anti-Xa activity. The relationship appears to be logarithmic with 17% of the variability in drug clearance explained by peak anti-Xa activity or dalteparin concentration ( Fig.  1) . No association between individual dalteparin anti-Xa clearance and gender, BMI, creatinine clearance, or baseline hematocrit was observed.
Attempts to fit the decay of anti-Xa activity to a first-order model agreed reasonably well with mean anti-Xa values after administration of the 40 and 60 IU/kg dose but performed poorly at early time points after the 80 IU/kg dose. A two-exponential decay model combining a fast (T 1 ⁄ 2 22 minutes) and slow (T 1 ⁄ 2 110 minutes) disappearance of plasma anti-Xa activity agreed with observed values after all doses (Fig. 2 ). However, for best agreement, the rapid decay could be applied only to a small, fixed quantity of anti-Xa activity. Low dynamic range and background activity of anti-IIa precluded use of non-compartmental methods to describe the disappearance of dal-teparin activity. Early values were fit to a monoexponential decay that was used for calculations. The T 1 ⁄ 2 of anti-IIa was shorter than the anti-Xa T 1 ⁄ 2 at any dose. Differential decay of antithrombin and anti-Xa resulted in a ratio of plasma Xa/IIa that increased after the dose was applied. 
Coagulation Times
The aPTT and LR-ACT increased after dalteparin administration in a dose dependent fashion ( Fig. 3) and displayed a good correlation with anti-Xa and anti-IIa activity ( Table 3 ). The correlation between coagulation time result and anti-Xa was not improved substantially by using the degree of prolongation of coagulation time or coagulation time/baseline ratio rather than the absolute value. The LR-ACT was imprecise near baseline limiting its dynamic range to anti-Xa activity values above approximately 1.0 IU/mL where its relationship is linear (Fig.  4) . The laboratory aPTT displayed far better precision near baseline values, allowing detection of lower concentration anti-Xa activities beginning its dynamic range around 0.7 IU/mL. An exponential relationship exists between anti-Xa activity and aPTT result with visible loss of precision at high concentration anti-Xa activity (Fig. 4) .
The sensitivity and specificity of specific absolute coagulation times for identification of above target anti-Xa activity was plotted to create ROC curves (Fig. 5) . The aPTT was superior to the LR-ACT in identifying anti-Xa activity above 0.5 IU/mL (p <0.0001), but was equivalent in detection of higher anti-Xa activities. In turn, the LR-ACT displayed superior discriminatory power to the standard ACT at lower anti-Xa activity but was equivalent at concentrations above 1.5 IU/mL. ROC curves were used to identify the most accurate aPTT and LR-ACT values discriminating threshold anti-Xa values, and the classification of dalteparin concentration range using coagulation times was compared to the classification using anti-Xa activity ( Table 4 ). When used as a categorical estimate of the intensity of anticoagulation, coagulation studies displayed fair agreement with measured anti-Xa concentration. For comparison, the agreement between anti-Xa and anti-IIa activity was similar (κ Xa-IIa: 0.69). 
DISCUSSION
Several single and multi-center registries have reported the use of enoxaparin or dalteparin anticoagulation during percutaneous coronary intervention (PCI), suggesting that unmonitored drug administration de novo or following a period of subcutaneous therapy may be safe and effective (1-7) . However, the pharmacokinetics of high-dose LMWH may be too complex to dose blindly or rely upon mathematical modeling and the observed correlation between dalteparin anti-Xa activity and coagulation times offers the opportunity to titrate therapy using standard point of care methods.
Pharmacokinetics
The clearance of LMWH is thought to differ from UFH in its reliance predominantly upon a slow, consistent renal mechanism. Reliable clearance and predictable volume of distribution and absorption allow drug administration without the need to monitor drug effect. We found the volume of distribution of high-dose intravenous dalteparin to be consistent and readily predicted using body weight but the rate of disappearance of anti-Xa activity varied slightly as a function of peak drug concentration. This variation is quite small and is unlikely to be of importance during routine anticoagulation using established subcutaneous dosing regimens. It is the probable explanation for this variation that is of greater importance.
Unfractionated heparin (UFH) is cleared from plasma by competing slow, non-saturable against fast, saturable mechanisms. The slow, non-saturable pathway depends on renal function while the fast, saturable mechanism is presumed to represent hepatic/endothelial or macrophage scavenger pathway uptake and depolymerization. The latter has an affinity for heparin molecules that is proportional to molecular weight and becomes saturated at unpredictable drug concentrations (9, 10) . As a result of these competing clearance mechanisms, the half-life of UFH varies with the dose applied. Similar behavior after high-dose dalteparin administration suggests that the fast, saturable clearance mechanisms with greater affinity for heavier heparin chains may influence the pharmacokinetics of high-dose LMWH therapy.
The concept that UFH-like pharmacokinetics may result in dose-related variation in LMWH clearance is in conflict with other reports in the literature using dalteparin and other LMWHs (9, (11) (12) (13) (14) (15) . However, most pharmacokinetic studies have concentrated on subcutaneous dosing, lower doses than may be effective during PCI, have not compared the behavior of different doses in the same individuals or have simply assumed first-order kinetics. In contrast, after the administration of three separate intravenous doses of ardeparin to each of 18 individuals, dose-sensitive clearance of anti-Xa activity similar to our observations was reported (16) .
LMWHs differ in their molecular size distribution, relative potency for Xa and IIa inhibition, and pharmacokinetics and cannot be discussed interchangeably. However, differential clearance of anti-Xa and anti-IIa activity with all LMWHs (13, 17, 18) , dose-sensitive variation in clearance of enoxaparin and nadroparin anti-IIa activity (1, 13, 18, 19) , and the distribution and clearance of various radiolabeled heparins (20) (21) (22) (23) (24) (25) all suggest that our report of dose-sensitive clearance with dalteparin may apply to the drug class. Available animal and human data support the hypothesis that the disappearance of anti-Xa and anti-IIa activity after administration of any heparin is a complex function of the interaction of at least two modes of elimination with different chain length affinity, the effect of molecular size upon AT-III inhibition of Xa and IIa, the availability of AT-III, and the size of heparin molecules in the preparation. This implies a mode of inter-individual variation in LMWH pharmacokinetics with high-dose therapy that may be shared by all LMWH preparations and that unlike renal function, is not identified with routine laboratory screening.
Monitoring
Contact-activated coagulation times such as the aPTT and ACT are commonly used to estimate plasma UFH concentration as a guide to drug administration. Despite incomplete correlation with anti-Xa activity and variability due to test method and reagents, both have proven valuable in the estimation of risk for thrombotic and hemorrhagic complications of UFH used to treat thrombotic illnesses and prevent complications associated with PCI (10, 26, 27) . Typical LMWH anticoagulation regimens produce a slight increase in the aPTT (3, 4, (28) (29) (30) , but the dynamic range and variables introduced by different reagents and test methods preclude its use for estimation of anti-Xa activity (29) .
Meanwhile, high-dose dalteparin and enoxaparin prolong the Hemochron ACT to a degree that suggests clinical utility as a monitoring test (1, 7, 8, 31) . After doses of dalteparin that may be used during PCI, we observed prolongation of both the aPTT and HemoTec LR-ACT proportional to drug concentration. The correlation between coagulation times and anti-Xa activity is comparable to the relationship between the aPTT and UFH (32) (33) (34) (35) .
Using coagulation times to assign a patient to categories of anticoagulation intensity compared to a similar classification using anti-Xa activity reveals that treatment decisions hinging on test outcome concur approximately 60% of the time. This too is similar to the reported performance of the aPTT and ACT in comparison to anti-Xa activity assessing UFH (33, 34) . Interestingly, the agreement between measured anti-Xa and anti-IIa activities is little better. The accuracy of monitoring studies is typically compared to anti-Xa with the assumption that heparin concentration, measured using plasma anti-Xa is a more accurate determinant of drug concentration, and therefore antithrombotic effect and bleeding risk. However, the actual importance of LMWH anti-Xa activity to antithrombotic effect and its value as a measure of antithrombotic effect are a matter of debate (36) (37) (38) (39) (40) (41) . These data establish that coagulation-based assays are useful as categorical estimates of dalteparin concentration during high-dose therapy measuring different or additional aspects of coagulation phenomenon than simply anti-Xa activity. High-dose dalteparin anticoagulation may be titrated to an aPTT or LR-ACT target range and the likelihood of dosing error is likely to be substantially lower than that which may occur based on mathematical modeling alone.
Limitations
In a relatively homogenous population of normal volunteers, without the confounding effects of drugs or clinical conditions that may be encountered in everyday practice, the expected variability in parameters that may alter drug kinetics and the relationship between coagulation times and drug concentration is limited. Additionally, the dalteparin doses were chosen to achieve an intensity of anticoagulation that is greater than that commonly achieved with subcutaneous dosing. The utility of the aPTT or LR ACT to differentiate dalteparin concentrations within the usual range of systemic anticoagulation was not assessed. With a large proportion of samples containing high concentrations of dalteparin, the apparent diagnostic value of the aPTT and LR ACT suggested by ROC curves is in-flated and the agreement reflected in the kappa statistic offers a more realistic expectation of test performance during high-dose therapy.
Although these data suggest that coagulationbased assays may be used as categorical estimates of dalteparin concentration, they do not establish a therapeutic range for coagulation times. Data provided by Marmur and colleagues (8) suggest that a target Hemochron ACT value of 175 to 200 seconds may be safe and effective but additional clinical trials are necessary.
CONCLUSION
Single dose, IV administration of dalteparin is associated with a relatively short half-life of drug effect and a volume of distribution that corresponds to the plasma compartment. Slight but significant variation in drug clearance associated with drug dose, a property that may be shared by all LMWH preparations, suggests that particularly when combining intravenous with subcutaneous dosing or when repeat doses may be desirable, monitored dose adjustment may improve the treatment efficacy of high-intensity anticoagulation therapy. Standard coagulation-based assays of heparin drug effect may be used to discriminate between broad ranges of plasma dalteparin concentrations with an apparent accuracy that is similar to that reported for UFH. Future study should be directed at establishing the LMWH anticoagulation intensity that is associated with maximum treatment safety and efficacy during invasive vascular procedures.
